Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970–2018

Johansson, Anna L.V.; Fredriksson, Irma; Mellemkjær, Lene; Stensheim, Hanne; Lähteenmäki, Päivi; Winther, Jeanette Falck; Ullenhag, Gustav; Lundberg, Frida E.

doi:10.1016/j.ejca.2021.07.008

Cited by 27 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There may also be biases, as the NCDB and NCCN Breast Cancer Outcomes DB are not population-based databases and only consider the care of those who had access to and received treatment at major academic cancer centers. Such biases can be ruled out in the exhaustive population-based registries of northern European countries such as Sweden, Norway, Finland, and Denmark [ 16 , 17 , 18 , 19 ]. We report here a much larger cohort of BC patients, which could be used for studies with high statistical power.…”

Section: Discussionmentioning

confidence: 99%

The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)

Dumas

Laot

Rejo

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death in women. The French National Cancer Institute has created a national cancer cohort to promote cancer research and improve our understanding of cancer using the National Health Data System (SNDS) and amalgamating all cancer sites. So far, no detailed separate data are available for early BC. Objectives: To describe the creation of the French Early Breast Cancer Cohort (FRESH). Methods: All French women aged 18 years or over, with early-stage BC newly diagnosed between 1 January 2011 and 31 December 2017, treated by surgery, and registered in the general health insurance coverage plan were included in the cohort. Patients with suspected locoregional or distant metastases at diagnosis were excluded. BC treatments (surgery, chemotherapy, targeted therapy, radiotherapy, and endocrine therapy), and diagnostic procedures (biopsy, cytology, and imaging) were extracted from hospital discharge reports, outpatient care notes, or pharmacy drug delivery data. The BC subtype was inferred from the treatments received. Results: We included 235,368 patients with early BC in the cohort (median age: 60 years). The BC subtype distribution was as follows: luminal (80.2%), triple-negative (TNBC, 9.5%); HER2+ (10.3%), or unidentifiable (n = 44,388, 18.9% of the cohort). Most patients underwent radiotherapy (n = 200,685, 85.3%) and endocrine therapy (n = 165,655, 70.4%), and 38.3% (n = 90,252) received chemotherapy. Treatments and care pathways are described. Conclusions: The FRESH Cohort is an unprecedented population-based resource facilitating future large-scale real-life studies aiming to improve care pathways and quality of care for BC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)

Dumas

Laot

Rejo

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…There may also be biases, as NCDB and NCCN Breast Cancer Outcomes DB are not population-based databases and only consider the care of those who had access to and received treatment at major academic cancer centers. Such biases can be ruled out in the exhaustive population-based registries of northern European countries such as Sweden, Norway, Finland and Denmark (de Boniface et al, 2021; Christiansen et al, 2016; Johansson et al, 2021; Leinonen et al, 2017). We report here a much larger cohort of BC patients, which could be used for studies with high statistical power.…”

Section: Discussionmentioning

confidence: 99%

“…European countries such as Sweden, Norway, Finland and Denmark (de Boniface et al, 2021;Christiansen et al, 2016;Johansson et al, 2021;Leinonen et al, 2017). We report here a much larger cohort of BC patients, which could be used for studies with high statistical power.…”

Section: Such Biases Can Be Ruled Out In the Exhaustive Population-ba...mentioning

confidence: 99%

The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS)

Dumas¹,

Laot²,

Coussy³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death in women. The French National Cancer Institute has created a national cancer cohort to promote cancer research and improve our understanding of cancer using the National Health Data System (SNDS). This cohort amalgamates all cancer sites, with no detailed separate data for early BC. Objectives: We describe the French Early Breast Cancer Cohort (FRESH). Methods: All French women aged 18 years or over, with early-stage BC newly diagnosed between January 1, 2011 and December 31, 2017, treated by surgery and registered in the general health insurance coverage plan were included in the cohort. Patients with suspected locoregional or distant metastases at diagnosis were excluded. BC treatments (surgery, chemotherapy, targeted therapy, radiotherapy, endocrine therapy), and diagnostic procedures (biopsy, cytology, imaging) were extracted from hospital discharge reports, outpatient care notes or pharmacy drug delivery data. BC subtype was inferred from the treatments received. Results: We included 235,368 patients with early BC in the cohort (median age: 60 years). BC subtype distribution was as follows: luminal (80.2%), triple-negative (TNBC, 9.5%); HER2+ (10.3%), or unidentifiable (n=44,388, 18.9% of the cohort). Most patients underwent radiotherapy (n=200,685, 85.3%) and endocrine therapy (n=165,655, 70.4%), and 38.3% (n=90,252) received chemotherapy. Treatments and care pathways are described. Conclusion: The FRESH Cohort is an unprecedented population-based resource facilitating future large-scale real-life studies aiming to improve care pathways and quality of care for BC patients.

show abstract

“…At present, there were still great differences in the prognosis of PABC. Data from Sweden showed that PABC was associated with a poor prognosis compared with non-PABC, comparing the 5-year and 10-year survival rates, it was found that the agestandardized survival rate of women with breast cancer during pregnancy was similar to that of non-PABC over time, while postpartum breast cancer was still lower [22]. Some studies had found similar results, suggesting that breast cancer diagnosed during pregnancy was a different entity from postpartum breast cancer, and the poor prognosis of PABC was mainly attributed to the poor prognosis of postpartum breast cancer [2,6,35].…”

Section: Introductionmentioning

confidence: 98%

Clinicopathological characteristics and prognosis of pregnancy-associated breast cancer: a multicenter retrospective study from the central China

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: This study aimed to compare the demographic and clinical characteristics of pregnancy-associated breast cancer (PABC) and non-PABC patients, and to analyze the prognostic factors. Methods: PABC patients ≤ 40 years old who were treated in three large tertiary institutions from January 1, 2016 to August 1, 2020 were included. The population and tumor characteristics of the patients were collected, and their survival were followed up. For each case, a non-PABC patient was matched as a control. Results: A total of 69 PABC patients and 69 non-PABC patients were included in the study. Compared with the non-PABC group, the clinical stage of PABC patients was later. In the univariate and multivariate analysis of all patients with breast cancer, it was found that the prognosis of PBAC patients was worse than that of controls and pregnancy correlation was not an independent factor affecting the prognosis of breast cancer. Moreover, there was no significant difference in clinicopathological characteristics between pregnancy and postpartum breast cancer. In the analysis of prognostic factors of PABC patients, we found that gestational weight gain (GWG) and vascular invasion were important factors affecting disease-free survival (DFS) of PABC patients, while oral contraceptive and clinical stage were important factors affecting their overall survival (OS). Conclusions: The prognosis of PABC patients was worse. However, pregnancy correlation was not an independent factor affecting the prognosis of breast cancer patients. Vascular invasion and inadequate or excessive gestational weight gain were important factors affecting recurrence and metastasis in PABC patients. Generally speaking, it is necessary to pay more attention to weight gain during pregnancy.

show abstract

Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970–2018

Cited by 27 publications

References 39 publications

The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)

The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS)

The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS)

Clinicopathological characteristics and prognosis of pregnancy-associated breast cancer: a multicenter retrospective study from the central China

Contact Info

Product

Resources

About